MERTK and lung carcinoma: MERTK blockade led to an overall reduction of metastasis burden as well as tumor growth in the brain, spine, liver, and hind limbs in the H460 lung cancer model, whereas in the MDA-MB-231 breast cancer model tumor growth was not statistically significantly affected (Fig. 6a–c and SFig. 17a, b).